Stetler-Stevenson M - Search Results

1

Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up.

Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, FitzGerald DJ, Santiago L, Gao G, Lanasa MC, Pastan I. Kreitman RJ, et al. Blood. 2018 May 24;131(21):2331-2334. doi: 10.1182/blood-2017-09-803072. Epub 2018 Feb 27. Blood. 2018. PMID: 29487070 Free PMC article.

2

Expression of mdr-1 in refractory lymphoma: quantitation by polymerase chain reaction and validation of the assay.

Kang YK, Zhan Z, Regis J, Alvarez M, Robey R, Meadows B, Dickstein B, Lee JS, Otsuki T, Stetler-Stevenson M, et al. Kang YK, et al. Blood. 1995 Aug 15;86(4):1515-24. Blood. 1995. PMID: 7632959 Free article. Clinical Trial.

3

Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study.

Sausville EA, Headlee D, Stetler-Stevenson M, Jaffe ES, Solomon D, Figg WD, Herdt J, Kopp WC, Rager H, Steinberg SM, et al. Sausville EA, et al. Blood. 1995 Jun 15;85(12):3457-65. Blood. 1995. PMID: 7780133 Free article. Clinical Trial.

4

Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study.

Foss FM, Borkowski TA, Gilliom M, Stetler-Stevenson M, Jaffe ES, Figg WD, Tompkins A, Bastian A, Nylen P, Woodworth T, et al. Foss FM, et al. Blood. 1994 Sep 15;84(6):1765-74. Blood. 1994. PMID: 8080984 Free article. Clinical Trial.

5

Tumor-infiltrating lymphocytes derived from select B-cell lymphomas secrete granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-alpha in response to autologous tumor stimulation.

Schwartzentruber DJ, Stetler-Stevenson M, Rosenberg SA, Topalian SL. Schwartzentruber DJ, et al. Blood. 1993 Aug 15;82(4):1204-11. Blood. 1993. PMID: 8353284 Free article.

6

Responses in refractory hairy cell leukemia to a recombinant immunotoxin.

Kreitman RJ, Wilson WH, Robbins D, Margulies I, Stetler-Stevenson M, Waldmann TA, Pastan I. Kreitman RJ, et al. Blood. 1999 Nov 15;94(10):3340-8. Blood. 1999. PMID: 10552943 Free article. Clinical Trial.

7

Hairy cell leukemia, a B-cell neoplasm that is particularly sensitive to the cytotoxic effect of anti-Tac(Fv)-PE38 (LMB-2).

Robbins DH, Margulies I, Stetler-Stevenson M, Kreitman RJ. Robbins DH, et al. Clin Cancer Res. 2000 Feb;6(2):693-700. Clin Cancer Res. 2000. PMID: 10690555

8

Development of lymphoproliferative disorder of granular lymphocytes in association with hairy cell leukemia.

Xie XY, Sorbara L, Kreitman RJ, Fukushima PI, Kingma DW, Stetler-Stevenson M. Xie XY, et al. Leuk Lymphoma. 2000 Mar;37(1-2):97-104. doi: 10.3109/10428190009057632. Leuk Lymphoma. 2000. PMID: 10721773

9

Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies.

Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe ES, Giardina S, Waldmann TA, Pastan I. Kreitman RJ, et al. J Clin Oncol. 2000 Apr;18(8):1622-36. doi: 10.1200/JCO.2000.18.8.1622. J Clin Oncol. 2000. PMID: 10764422 Clinical Trial.

10

Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.

Kreitman RJ, Margulies I, Stetler-Stevenson M, Wang QC, FitzGerald DJ, Pastan I. Kreitman RJ, et al. Clin Cancer Res. 2000 Apr;6(4):1476-87. Clin Cancer Res. 2000. PMID: 10778980

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

244 results

Search Page

Filters